We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Iq-ai Limited | LSE:IQAI | London | Ordinary Share | JE00BD4H0R42 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.55 | 1.50 | 1.60 | 1.55 | 1.55 | 1.55 | 113,265 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Florists | 536k | -512k | -0.0028 | -5.54 | 2.83M |
From Apr 2022 to Apr 2024
By Elena Vardon
IQ-AI Ltd. shares rose 23% on Tuesday after the company said it has received orphan drug designation status from the U.S. Food and Drug Administration for its treatment for brain cancer.
At 1608 GMT, shares were up 0.70 pence at 3.80 pence.
The U.K. medical-software and services company said the status is given to drugs showing promise in treating rare diseases or conditions that affect less than 200,000 people in the U.S.
The group said enrollment in the Phase I clinical trial to evaluate the safety and tolerability of gallium maltolate in the treatment of glioblastoma multiforme brain cancer is continuing.
"This designation is a critical milestone in the development of GaM. It brings the possibility of making an oral agent available as a treatment option for glioblastoma multiforme brain cancer, closer to reality," Chief Executive Trevor Brown said.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
February 28, 2023 11:43 ET (16:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Iq-ai Chart |
1 Month Iq-ai Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
